CO-FORTIUS-METALS-INC
6.12.2022 17:01:43 CET | Business Wire | Press release
Fortius Metals, Inc., an innovative metal 3D printing company, has announced today that it has closed on a priced seed financing round with AM Ventures. The $2M round will be used to scale manufacturing capacity, grow the company and accelerate its go-to-market strategy.
Fortius Metals is a large format additive manufacturing company that specializes in advanced materials to help customers develop solutions previously not possible with robotic 3D printing. Fortius Metals’ patented technology will enable welding and 3D wire fabrication using high performance metal alloys to meet the exacting demands of aerospace customers and robotic welding fabricators.
AM Ventures, the foremost venture capital firm for the additive manufacturing sector, focuses solely on startups built around industrial-grade 3D printing offerings, including hardware, software, materials, and applications. AM Ventures’ portfolio includes an elite group of 17 companies engaged in 3D printing, out of over 2,400 start-ups evaluated.
“We are looking forward to supplying customers who are already requesting our proprietary 6061 aluminum welding wire that solves traditional 'hot cracking' problems,” said Jeff Lints, Fortius CEO. “We are proud to be a Colorado company along with many of our space and aircraft customers.”
Fortius welds are often twice the strength of incumbent commercial options for welding and 3D printing, which will help customers increase design performance, improve product quality and reduce weight.
“We strongly believe that large scale additive manufacturing has massive potential. But until we spoke to Fortius we had not seen an investment opportunity that could accelerate adoption,” said Philip Schultheiss, Senior Associate at AM Ventures. “Jeffrey and his talented team are developing not only a way of making high strength metals readily available for large scale printing and traditional welding but also increasing their mechanical properties, an investment was just logical.” Fortius Metals’ position as a potential supplier to technologically cutting-edge aerospace and defense customers inspired AM Ventures to navigate complex CFIUS clearance rules for their investment in order to open the door to a long-term partnership with Fortius.
Fortius is a spinout from Elementum 3D, headquartered in Erie, CO, which has already patented and commercialized this technology for powder bed fusion additive manufacturing. Fortius was formed to develop nanostructured metal alloy wires for use in robotic additive manufacturing applications – representing new markets and new products. The company’s vision is to use advanced materials technology to re-shore the metal manufacturing supply chain while supporting highly skilled jobs in American factories.
For more information on Fortius Metals, contact CEO Jeff Lints at
jeff@fortiusmetals.com or (303) 913-9526
About Fortius Metals
Fortius Metals is a large format additive manufacturing company specializing in new materials. These patented, groundbreaking metal alloys will enable aerospace, automotive, and defense customers to meet the demands of high-performance applications.
About AM Ventures
AM Ventures, the leading venture capital firm in industrial additive manufacturing, has backed 20+ successful companies in 7 countries on 3 continents. The team possesses in-depth technology know-how and is well connected with the most experienced experts in the field. As an investment partner, the company provides a globally leading ecosystem of sustainable investments in additive manufacturing and introduces entrepreneurs to a large pool of industry veterans, each one with decades of experience in engineering, manufacturing and executive management. Since 2021, AM Ventures is set up as a venture capital fund.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221206005018/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom